Cargando…

Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms

OBJECTIVE: Primary myelofibrosis (PMF) is one of the Philadelphia negative myeloproliferative neoplasms (MPN). The main clinical features are obvious physical symptoms and symptomatic splenomegaly. It may be converse to leukemia and has a shortened life expectancy. Nowadays, the therapy for PMF is a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Xingnong, Chen, Dan, Zheng, Yan, Zhu, Xiaoqiong, Fu, Junkai, Huang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5692198/ https://www.ncbi.nlm.nih.gov/pubmed/29180875 http://dx.doi.org/10.2147/OTT.S142561

Ejemplares similares

Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS
por: Luo, Shuna, et al.
Publicado: (2020)

The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population‐based study
por: Ye, Xingnong, et al.
Publicado: (2019)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
por: Mandhan, Nikeeta, et al.
Publicado: (2021)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
por: Wan, Ziqi, et al.
Publicado: (2020)

Myelodysplastic syndrome/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis
por: Tasleem, Azka, et al.
Publicado: (2021)

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
por: Palomo, Laura, et al.
Publicado: (2021)

Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
por: Clara, Joseph A., et al.
Publicado: (2016)

Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
por: Person, Fermin, et al.
Publicado: (2021)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone
por: Ye, Li, et al.
Publicado: (2017)

Characteristics of the four subtypes of myelodysplastic/myeloproliferative neoplasms
por: WU, HUANLING, et al.
Publicado: (2013)

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
por: Romano, Michela, et al.
Publicado: (2017)

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
por: Malcovati, Luca, et al.
Publicado: (2011)

Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes
por: Brecqueville, M, et al.
Publicado: (2011)

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
por: Qin, Taichun, et al.
Publicado: (2011)

Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms
por: Hochman, Michael J., et al.
Publicado: (2021)

Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes
por: DING, KAI, et al.
Publicado: (2016)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

Spotlight on decitabine for myelodysplastic syndromes in Chinese patients
por: Jing, Yu, et al.
Publicado: (2015)

Nontraumatic acute subdural hematoma associated with the myelodysplastic/myeloproliferative neoplasms
por: Ichimura, Shinya, et al.
Publicado: (2012)

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms
por: Gerke, Margo B., et al.
Publicado: (2023)

P1010: PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS HAVE INCREASED NUMBERS OF MYELOID-DERIVED SUPPRESSOR CELLS, AND DECITABINE MAY HAVE A SIGNIFICANT THERAPEUTIC EFFECT IN MPN PATIENTS WITH HIGH MDSCS
por: Feng, Qiutian, et al.
Publicado: (2023)

Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies
por: Brune, Magdalena M., et al.
Publicado: (2021)

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial
por: Liu, Hui, et al.
Publicado: (2023)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
por: Garcia, Jacqueline S, et al.
Publicado: (2010)

Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes
Publicado: (2022)

Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms
por: Lim, Sung-Nam, et al.
Publicado: (2013)

Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
por: Hu, Naibo, et al.
Publicado: (2021)

Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases
por: Popov, Hristo, et al.
Publicado: (2022)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Clinical effect of decitabine in the treatment of myelodysplastic syndrome and influencing factors
por: Liu, Tangxia, et al.
Publicado: (2020)

Atypical chronic myeloid leukaemia – a rare subtype of myelodysplastic/myeloproliferative neoplasm
por: Drozd-Sokołowska, Joanna E., et al.
Publicado: (2018)

Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count
por: Divoux, Marion, et al.
Publicado: (2020)

Anemia with thrombocytosis in an elderly male: a case of myelodysplastic syndrome-myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis
por: Kumar, Ashutosh, et al.
Publicado: (2018)

Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms
por: O‘Hagan Henderson, Samantha, et al.
Publicado: (2021)

A novel treatment regimen of granulocyte colony-stimulating factor combined with ultra-low-dose decitabine and low-dose cytarabine in older patients with acute myeloid leukemia and myelodysplastic syndromes
por: Zhu, Huan, et al.
Publicado: (2021)

Decitabine Induces Change of Biological Traits in Myelodysplastic Syndromes via FOXO1 Activation
por: Zhang, Zheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b0qvce0mkt21s1cgp91gs89atj